IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have reached a definitive agreement to create a global orthobiologics leader. The combination would create a comprehensive orthobiologics portfolio, one of the largest sales organizations focused on orthobiologics in the US, and multiple cross-selling opportunities. The transaction is subject to approval of IsoTis' stockholders, as well as other closing conditions and approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of Integra and Integra will be one of the largest companies in the world focused on advanced technology in orthobiologics.
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities Exchange
Act of 1934, as amended, including those that refer to management's plans
and expectations for, among other things, future operations, strategies,
prospects, performance and financial condition and IsoTis' proposed
acquisition by Integra. Words such as "strategy," "expects," "plans,"
"anticipates," "believes," "may," "will," "might," "could," "would,"
"continues," "estimates," "intends," "pursues," "projects," "goals,"
"targets" or the negative or other variations thereof and other words of
similar meaning are intended to identify such forward-looking statements.
|SOURCE IsoTis Inc|
Copyright©2007 PR Newswire.
All rights reserved